Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa

Azwidihwi Takalani,Michelle Robinson,Phumeza Jonas,Annie Bodenstein,Vuyelo Sambo,Barry Jacobson,Vernon Louw,Jessica Opie,Jonny Peter,Pradeep Rowji,Ishen Seocharan,Tarylee Reddy,Nonhlanhla Yende-Zuma,Kentse Khutho,Ian Sanne,Linda-Gail Bekker,Glenda Gray,Nigel Garrett,Ameena Goga

DOI: https://doi.org/10.1016/j.vaccine.2024.01.066

IF: 4.169

2024-01-26

Vaccine

Abstract:The Sisonke 2 study provided a homologous boost at least 6 months after administration of the priming dose of Ad26.COV2.S for healthcare workers enrolled on the Sisonke phase 3b implementation study. Safety monitoring was via five reporting sources: (i.) self-report through a web-link; (ii.) paper-based case report forms; (iii.) a toll-free telephonic reporting line; (iv.) healthcare professionals-initiated reports; and (v.) active linkage with National Disease Databases. A total of 2350 adverse events were reported by 2117 of the 240 888 (0.88%) participants enrolled; 1625 of the 2350 reported events are reactogenicity events and 28 adverse events met seriousness criteria. No cases of thrombosis with thrombocytopaenia syndrome were reported; all adverse events including thromboembolic disorders occurred at a rate below the expected population rates apart from one case of Guillain Barre Syndrome and one case of portal vein thrombosis. The Sisonke 2 study demonstrates that two doses of Ad26.COV2.S is safe and well tolerated; and provides a feasible model for national pharmacovigilance strategies for low- and middle-income settings.

immunology,medicine, research & experimental